menu
    • menu
    [{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celtaxsys, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celtaxsys, Inc. \/ Celerion"},{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Clinical Network Services | Linear | CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Clinical Network Services | Linear | CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Celtaxsys, Inc. \/ Clinical Network Services | Linear | CPR Pharma Services"},{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Clinical Network Services | Celtaxsys Aus Pty Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Dermatology","graph2":"Phase II","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Clinical Network Services | Celtaxsys Aus Pty Limited","highestDevelopmentStatusID":"8","companyTruncated":"Celtaxsys, Inc. \/ Clinical Network Services | Celtaxsys Aus Pty Limited"},{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celtaxsys, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Celltaxis","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Immunology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Stanford University \/ Celltaxis","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Celltaxis"}]

    Find Clinical Drug Pipeline Developments & Deals for Acebilustat

    Menu

    Acebilustat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stanford University

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Stanford University

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Celltaxis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of Acebilustat for the Treatment of Upper Arm Lymphedema

                            Details : Acebilustat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphedema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2022

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Celltaxis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibr...

                            Details : CTX-4430 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2015

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Clinical Network Services | Celtaxsys Aus Pty Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris

                            Details : CTX-4430 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2015

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Clinical Network Services | Celtaxsys Aus Pty Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat,Midazolam

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam

                            Details : CTX-4430 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2014

                            Lead Product(s) : Acebilustat,Midazolam

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients

                            Details : CTX-4430 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 18, 2013

                            Lead Product(s) : Acebilustat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Celerion

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Celtaxsys, Inc.

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebilustat,Mannitol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Clinical Network Services | Linear | CPR Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study Assessing the Safety and Tolerability of CTX-4430

                            Details : CTX-4430 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pneumonia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 13, 2012

                            Lead Product(s) : Acebilustat,Mannitol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Clinical Network Services | Linear | CPR Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.